https://www.globenewswire.com/news-release/2022/01/27/2374277/0/en/Yamo-Pharmaceuticals-Announces-Enrollment-of-First-Patient-in-Phase-2-Study-of-L1-79-in-Autism-Spectrum-Disorder.html